Patients & CaregiversHealthcare Professionals - Opens new windowWorldwide - Opens new window
Quick Find - Click to open on a page
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
Contact us Contact Newsroom
Podcasts Podcast
RSS RSS

Product News

These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

FOSAMAX® (alendronate sodium tablets)

14 Sep 2007  Statement by Merck & Co., Inc. Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw

GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
26 May 2009  GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification
09 Jan 2009  Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45

Janumet™ (sitagliptin/metformin HCl) tablets

Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
08 Jun 2009  Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes

Januvia™ (sitagliptin)

Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
06 Jun 2009  In Investigational Studies, New Uses of JANUVIA™ (sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes

SINGULAIR® (montelukast)

Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
12 Jun 2009  Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
29 May 2009  Merck Statement on United States Patent & Trademark Office Decision to Reexamine the SINGULAIR® Patent
13 Jan 2009  Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast)

top

*Software to view files presented in PDF or SWF format is available at no charge through the Adobe Web site. Get Adobe Reader Get Adobe Flash Player

Printer Friendly Page
 
Contact Merck Site Map Accessibility Statement Privacy Policy Terms of Use Copyright 1995-2008 Merck & Co., Inc.